SBSimon P. Boni

Simon P. Boni

*This is an algorithmically generated author record based on publicly available information.

Simon P. Boni has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Implementing HPV Testing and Thermal Ablation on the Cascade of Cervical Cancer Screening Program by HIV Status in Côte d’Ivoire: An Interrupted Time Series analysis

    by Simon Boni, Thomas D'AQuin Toni, Mesmin Adie, See Pdf

    Introduction: Cervical cancer (CC) remains a major cause of cancer mortality among women in developing countries. Human papillomavirus (HPV) based screening has been promoted but real-world assessments at country-level are lacking. We assessed the impact of implementing HPV testing and thermal ablation on CC screening cascade by HIV status, in Côte d'Ivoire.Methods: An interrupted time-series (ITS) analysis using programmatic data from January 2018 to November 2023 across 43 health facilities was conducted. The pre-intervention period corresponded to visual inspection based “screen-and-treat” with cryotherapy; the post-intervention period corresponded to HPV testing and thermal ablation implementation. Step and slope changes in monthly screening volume and same-day treatment rate were assessed using Negative binomial and Poisson ITS regression models respectively, estimating risk ratios (IRR).Findings: A total of 64,887 screening episodes were recorded. Among women who tested HPV-positive, 25·9% attended the triage visit. HPV-based screening was associated with a 5·2-fold increase in monthly screening volume (95% CI: [3·28–8·28]). The step effect was greater among women living with HIV-WLHIV (IRR: 22·4; 95% CI: [12·96–38·34]) compared to women without HIV (IRR: 4·39; 95% CI: [2·63–7·33]), while the declining in slopes was greater in WLHIV (IRR: 0·94; 95% CI: [0·91–0·97]). The adjusted step effect of thermal ablation on treatment access was 2·27-fold (95% CI: [1·88 – 2·73]); slope changes were sustained in women without HIV (IRR: 1·03; 95% CI: [1·02–1·04]), and in those screened in primary healthcare (PHC) facilities (IRR: 1·02; 95% CI: [1·01–1·03]), but not among WLHIV (IRR: 0·96; 95% CI: [0·89–1·03]).Interpretation: Transitioning to HPV-testing was associated with an immediate increase in screening uptake, but high attrition in triage visit completion. Thermal ablation showed high effectiveness in accessing treatment supporting targeted investments at the PHC level.

  • Open Access

    Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium

    by Rachael A. Pellegrino, Bryan E. Shepherd, Sanjay Pujari, Valeria Fink, Gad Murenzi, Miriam Nakalembe, Sally B. Coburn, Eliane Rohner, Antoine Jaquet, Caroline Lade, et al.

    Cancer remains a leading cause of morbidity and mortality in people with HIV, and the importance of cancer screening increases as this population ages. In 2017, 2020, and 2023, cross‐sectional surveys were conducted at HIV care sites across 5 continents within the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. We described cancer screening availability in 2023 and over time for cervical and anal cancer screening using generalized estimating equations with a logit link function to account for site clustering, rurality, and country income. Of the 220 sites in the 2023 survey, 61% (134/220) reported cervical cancer screening by cytology or human papillomavirus (HPV) testing on‐site, and 88% (194/220) reported cervical cancer screening by any method, including visual inspection. At sites serving predominantly rural populations, 62% (29/47) exclusively performed screening by visual inspection. Overall, 23% (50/220) of sites performed cytology‐based anal cancer screening on‐site, and 16% (35/220) had availability of high‐resolution anoscopy, either on‐site or by referral. Screening for cancer of the liver, colon, lung, prostate, or breast (by imaging) were each available at less than 43% of sites. The odds of cervical cancer screening availability increased by 16% annually from 2017 through 2023 (aOR = 1.16, 95% CI: 1.07–1.27, p = 0.001), while the relative odds of anal cancer screening availability decreased by 9% annually (aOR = 0.91, 95% CI: 0.84–0.99, p = 0.023). Lack of trained staff was the most frequently reported barrier, followed by lack of equipment. Understanding current practices and capacity is essential for the continued integration of cancer prevention in HIV care.


  • Open Access

    Cervical Cancer Screening Cascade in Côte d’Ivoire: A Decade of Real-World Program Evaluation According to HIV Status

    by Simon Boni, David Goore, Mesmin Adie, Franck Gnahatin, Denise Kpebo, Apollinaire Horo, Innocent Adoubi, Antoine Jaquet, on behalf The IeDEA West Africa Collaboration

    PURPOSE: We assessed progress toward WHO 2030 Cervical Cancer (CC) elimination targets including 70% coverage for CC screening and 90% of precancerous lesions treated according to HIV status in Côte d’Ivoire during the 2010-2021 period. METHODS: A national CC screening registry was initiated in Côte d’Ivoire since 2010, collecting individual-level data from all health facilities offering visual inspection with acetic acid (VIA). The CC screening coverage was estimated based on the 2021 population census and the HIV national database in women aged 25-49 years from the general population and in women with HIV (WLHIV). CC screening and care cascade indicators were documented over time and compared according to HIV status. Access to same-day cryotherapy and associated factors were analyzed through a logistic regression model. RESULTS: A total of 66,268 women received CC screening, with 11,251 (17.0%) being WLHIV. The estimated CC screening coverage was 4.4% (2.6-5.2), rising to 13.9% (13.5-15.3) in WLHIV. Overall, VIA positivity was 6.4% (6.2-6.5) and was higher in WLHIV (9.1% [8.6-9.7]), P < .001. Among VIA-positive women, 3,500 (83.1%) were eligible for same-day cryotherapy. Access to cryotherapy was 59.1%, declining over time from 71.7% before 2015 to 51.9% in 2021. Access to cryotherapy was higher in WLHIV (aOR, 1.55 [95% CI, 1.32 to 1.84]) and women screened in secondary-level (aOR, 1.82 [95% CI, 1.49 to 2.23]) or tertiary-level facilities (aOR, 1.79 [95% CI, 1.54 to 2.09]) versus primary level. CONCLUSION: Despite major achievements in this 11-year implementation of the CC screening program in Côte d’Ivoire, performances remained low regardless of HIV status and far from elimination targets in 2021. These findings underline the need to endorse new screening strategies based on HPV testing and thermal ablation treatment at a national level.

  • Open Access

    High‐risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Côte d'Ivoire, 2018 to 2020

    by Simon P. Boni, Vanessa Tenet, Apollinaire Horo, Daniëlle A. M. Heideman, Maaike C. G. Bleeker, Aristophane Tanon, Boston Mian, Isidore D. Mohenou, Didier K. Ekouevi, Tarik Gheit, et al.

    As human papillomavirus (HPV) immunisation and HPV‐based cervical cancer (CC) screening programmes expand across sub‐Saharan Africa, we investigated the potential impact of human immunodeficiency virus (HIV) status on high‐risk (HR)‐HPV distribution among women with CC in Côte d'Ivoire. From July 2018 to June 2020, paraffin‐embedded CC specimens diagnosed in Abidjan, Côte d'Ivoire were systematically collected and tested for HR‐HPV DNA. Type‐specific HR‐HPV prevalence was compared according to HIV status. Of the 170 CC specimens analysed (median age 52 years, interquartile range: [43.0‐60.0]), 43 (25.3%) were from women living with HIV (WLHIV) with a median CD4 count of 526 [373‐833] cells/mm3 and 86% were on antiretroviral therapy (ART). The overall HR‐HPV prevalence was 89.4% [95% CI: 84.7‐94.1]. All were single HR‐HPV infections with no differences according to HIV status (P = .8). Among HR‐HPV‐positive CC specimens, the most prevalent HR‐HPV types were HPV16 (57.2%), HPV18 (19.7%), HPV45 (8.6%) and HPV35 (4.6%), with no significant differences according to HIV status. Altogether, infection with HPV16/18 accounted for 71.1% [95% CI: 55.9‐86.2] of CC cases in WLHIV vs 78.9% [95% CI: 71.3‐86.5] in women without HIV (P = .3). The study confirms the major role of HPV16/18 in CC in Côte d'Ivoire and should support a regional scale‐up of HPV16/18 vaccination programmes regardless of HIV status. However, vaccines targeting additional HR‐HPV types, including HPV45 and HPV35, could further decrease future CC incidence in Côte d'Ivoire, both for WLHIV and women without HIV.


  • Open Access

    Impact of HIV infection on access to cancer care and survival among women with invasive cervical cancer in Côte d'Ivoire: A prospective cohort study

    by Simon P. Boni, Apollinaire Horo, Judith Didi‐Kouko‐Coulibaly, Aristophane Tanon, Boris K. Tchounga, Patrick A. Coffie, Jean‐Claude Comoe, Raoul D. Moh, François Dabis, Innocent Adoubi, et al.

    ObjectiveTo assess the impact of HIV on access to invasive cervical cancer (ICC) care and overall survival (OS) in a time of universal access to antiretroviral therapy (ART). MethodsA cohort of women prospectively diagnosed with ICC was consecutively recruited from 2018 to 2020 in public/private cancer centers in Cote d'Ivoire. Follow-up data were collected through facility- and phone-based approaches. Logistic and Cox regression models allowed analysis of factors associated with access to cancer care and OS, respectively. ResultsOverall, 294 women with ICC aged 50 years (interquartile range [IQR] 43-60) were enrolled, including 21.4% of women living with HIV (WLHIV), 87% being on ART. An advanced ICC clinical stage (III-IV) was less frequent in WLHIV (63.5% vs. 77.1% in HIV-uninfected women; P = 0.029). Cancer care was initiated in 124 (42.2%) women (54.0% in WLHIV; 39.0% in HIV-uninfected; P = 0.030). Factors independently associated with access to cancer care were International Federation of Gynecology and Obstetrics (FIGO) stage I-II (adjusted odds ratio [aOR] 3.58, 95% CI 2.01-6.38) and no treatment by traditional healers prior to ICC diagnosis (aOR 3.69, 95% CI 1.96-6.96). The 2-year OS was 37.9% (95% CI 30.0-47.9). HIV status was not predictive of mortality (adjusted hazard ratio [aHR] 0.98, 95% CI 0.60-1.69). An advanced clinical stage was the only measured predictor of death (aHR 1.59, 95% CI 1.02-2.47). ConclusionIn a time of universal access to ART, HIV infection was not associated with OS among women with ICC in Cote d'Ivoire. Higher access to cancer care in WLHIV might be mediated by enhanced access to ICC screening services, supporting the need to expand these services to other types of healthcare facilities.


  • Open Access

    Barriers and facilitators in cervical cancer screening uptake in Abidjan, Côte d'Ivoire in 2018: a cross-sectional study

    by Simon P. Boni, Franck Gnahatin, Jean-Claude Comoé, Boris Tchounga, Didier Ekouevi, Apollinaire Horo, Innocent Adoubi, Antoine Jaquet

    Cervical cancer (CC) incidence remains unacceptably high in Côte d’Ivoire. In an effort to prevent this malignant condition, a national CC screening program has been scaled up in the country. This study aimed at assessing CC screening uptake and its associated factors in Abidjan in 2018. A cross-sectional survey was conducted from July to September 2018 in the main healthcare facilities of three randomly selected out of the eight health districts of Abidjan. During the study period, a standardized questionnaire was administrated by research assistants to all women aged 25 to 55 years old, attending the three participating facilities. Demographics, knowledge on CC, personal history of CC screening and reasons for not attending CC screening were collected. A logistic regression model was computed to document factors associated with reported CC screening uptake. A total of 1158 women with a median age of 32 years (IQR [27–36]), including 364 (31.4%) with no formal education were included. Of those participants, 786 (67.9%) had ever heard about CC. CC screening uptake at least once was reported by 7.5% [95% CI: 6.0–9.0] participants. In multivariable analysis, being ≥45 years (aOR: 6.2 [2.3–17.2]), having a university level (aOR: 2.8 [1.2–6.6]) (versus non formal education) and access to mass campaign information (aOR: 18.2 [8.5–39.1]) were associated with a reported CC screening uptake. The main reported barriers to CC screening were unawareness towards CC screening (75.5%), negligence (20.5%), fear of CC detection (3.9%) and fear of additional costs (3.3%). CC screening uptake remains low despite current initiatives to support awareness and prevention in Abidjan. Awareness campaigns need to be massively increased with the adjunction of tailored messages based on the level of women’s education to enhance the CC screening coverage and reach the WHO goal of CC elimination by 2030.


  • Open Access

    Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries

    by Phillipe Lepère, Yélamikan Touré, Alexandra M Bitty-Anderson, Simon P Boni, Gildas Anago, Boris Tchounga, Pendadiago Touré, Albert Minga, Eugène Messou, Guillaume Kanga, et al.

    Background: The use of mobile technology in health care (mobile health [mHealth]) could be an innovative way to improve health care, especially for increasing retention in HIV care and adherence to treatment. However, there is a scarcity of studies on mHealth among people living with HIV (PLHIV) in West and Central Africa. Objective: The aim of this study was to assess the acceptability of an mHealth intervention among PLHIV in three countries of West Africa. Methods: A cross-sectional study among PLHIV was conducted in 2017 in three francophone West African countries: Côte d’Ivoire, Burkina Faso, and Togo. PLHIV followed in the six preselected HIV treatment and care centers, completed a standardized questionnaire on mobile phone possession, acceptability of mobile phone for HIV care and treatment, preference of mobile phone services, and phone sharing. Descriptive statistics and logistic regression were used to describe variables and assess factors associated with mHealth acceptability. Results: A total of 1131 PLHIV—643 from Côte d’Ivoire, 239 from Togo, and 249 from Burkina Faso—participated in the study. Median age was 44 years, and 76.1% were women (n=861). Almost all participants owned a mobile phone (n=1107, 97.9%), and 12.6% (n=140) shared phones with a third party. Acceptability of mHealth was 98.8%, with the majority indicating their preference for both phone calls and text messages. Factors associated with mHealth acceptability were having a primary school education or no education (adjusted odds ratio=7.15, 95% CI 5.05-10.12; P<.001) and waiting over one hour before meeting a medical doctor on appointment day (adjusted odds ratio=1.84, 95% CI 1.30-2.62; P=.01). Conclusions: The use of mHealth in HIV treatment and care is highly acceptable among PLHIV and should be considered a viable tool to allow West and Central African countries to achieve the Joint United Nations Programme on HIV/AIDS 90-90-90 goals.


  • Open Access

    Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries (Preprint)

    by Phillipe Lepère, Yélamikan Touré, Alexandra M Bitty-Anderson, Simon P Boni, Gildas Anago, Boris Tchounga, Pendadiago Touré, Albert Minga, Eugène Messou, Guillaume Kanga, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The use of mobile technology in health care (mobile health [mHealth]) could be an innovative way to improve health care, especially for increasing retention in HIV care and adherence to treatment. However, there is a scarcity of studies on mHealth among people living with HIV (PLHIV) in West and Central Africa. Objective: The aim of this study was to assess the acceptability of an mHealth intervention among PLHIV in three countries of West Africa. Methods: A cross-sectional study among PLHIV was conducted in 2017 in three francophone West African countries: Côte d’Ivoire, Burkina Faso, and Togo. PLHIV followed in the six preselected HIV treatment and care centers, completed a standardized questionnaire on mobile phone possession, acceptability of mobile phone for HIV care and treatment, preference of mobile phone services, and phone sharing. Descriptive statistics and logistic regression were used to describe variables and assess factors associated with mHealth acceptability. Results: A total of 1131 PLHIV—643 from Côte d’Ivoire, 239 from Togo, and 249 from Burkina Faso—participated in the study. Median age was 44 years, and 76.1% were women (n=861). Almost all participants owned a mobile phone (n=1107, 97.9%), and 12.6% (n=140) shared phones with a third party. Acceptability of mHealth was 98.8%, with the majority indicating their preference for both phone calls and text messages. Factors associated with mHealth acceptability were having a primary school education or no education (adjusted odds ratio=7.15, 95% CI 5.05-10.12; P<.001) and waiting over one hour before meeting a medical doctor on appointment day (adjusted odds ratio=1.84, 95% CI 1.30-2.62; P=.01). Conclusions: The use of mHealth in HIV treatment and care is highly acceptable among PLHIV and should be considered a viable tool to allow West and Central African countries to achieve the Joint United Nations Programme on HIV/AIDS 90-90-90 goals.